Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer | Synapse
September 13, 2024
Supplementary Figure S4 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer
Key Points
Key points are not available for this paper at this time.
Abstract
ctDNA tumor fraction to prognosticate overall survival on enzalutamide post-abiraterone by treatment arm